Value of the risk of ovarian malignancy algorithm index in predicting the recurrence of epithelial ovarian cancer

Biomark Med. 2022 Oct;16(14):1055-1066. doi: 10.2217/bmm-2022-0287. Epub 2022 Sep 5.

Abstract

Aim: This study aimed to assess the predictive and diagnostic value of the risk of ovarian malignancy algorithm (ROMA) index for epithelial ovarian cancer (EOC) recurrence. Materials & methods: The clinical features and follow-up data of 159 EOC cases were studied. The ROMA index was calculated by serum CA125 and HE4 levels with menopausal status. Recurrence-free survival was evaluated for an end point. Results: The ROMA was strongly associated with clinical characteristics. The ROMA index above the cutoff value (34.71%) was significantly associated with recurrence-free survival. The ROMA index had a significantly higher sensitivity (90.59%) than CA125 (84.71%) and HE4 (80.80%) for recurrence diagnosis, and its optimal cutoff value was 17.07%. Conclusion: The primary ROMA index is a predictive factor in EOC recurrence and has better performance in the diagnosis of EOC recurrence.

Keywords: CA125; FIGO; HE4; ROMA index; epithelial ovarian cancer; recurrence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Biomarkers, Tumor
  • CA-125 Antigen
  • Carcinoma, Ovarian Epithelial / diagnosis
  • Female
  • Humans
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / pathology
  • Proteins*
  • WAP Four-Disulfide Core Domain Protein 2

Substances

  • Proteins
  • Biomarkers, Tumor
  • WAP Four-Disulfide Core Domain Protein 2
  • CA-125 Antigen